Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.5 USD | +1.34% | +3.08% | +90.12% |
09/05 | Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating | MT |
08/05 | Transcript : Tarsus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
Summary
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+90.12% | 145.46Cr | C- | ||
+31.37% | 60TCr | B | ||
-2.60% | 37TCr | C+ | ||
+20.83% | 33TCr | B- | ||
+5.69% | 29TCr | C+ | ||
+14.83% | 24TCr | B+ | ||
+9.93% | 21TCr | B- | ||
-6.95% | 20TCr | A+ | ||
+10.77% | 17TCr | C+ | ||
+0.10% | 16TCr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TARS Stock
- Ratings Tarsus Pharmaceuticals, Inc.